We are live on ! Find out more
PTCT icon

PTC Therapeutics

207 hedge funds and large institutions have $3.52B invested in PTC Therapeutics in 2021 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 75 increasing their positions, 82 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,273% more call options, than puts

Call options by funds: $12.3M | Put options by funds: $894K

9% less repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 82

1.83% less ownership

Funds ownership: 107.24%105.41% (-1.8%)

3% less funds holding

Funds holding: 214207 (-7)

13% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 32

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

21% less capital invested

Capital invested by funds: $4.46B → $3.52B (-$946M)

Holders
207
Holders Change
-7
Holders Change %
-3.27%
% of All Funds
3.63%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.11%
New
28
Increased
75
Reduced
82
Closed
32
Calls
$12.3M
Puts
$894K
Net Calls
+$11.4M
Net Calls Change
+$752K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$499M +$19.9M +334,493 +3%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$435M -$8.82M -148,522 -2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$303M +$11.2M +187,889 +3%
BlackRock
4
BlackRock
New York
$294M +$10.8M +182,088 +3%
Franklin Resources
5
Franklin Resources
California
$259M -$5.76M -96,981 -2%
RI
6
RTW Investments
New York
$251M +$63.7M +1,072,130 +25%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$145M +$4.32M +72,719 +2%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$102M -$3.45M -58,143 -3%
State Street
9
State Street
Massachusetts
$96.2M -$8.89M -149,739 -7%
AllianceBernstein
10
AllianceBernstein
Tennessee
$81.3M -$3.35M -56,430 -3%
AC
11
Armistice Capital
New York
$66.1M +$40.4M +680,000 +95%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$55.4M +$11.6M +195,412 +20%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$54.4M +$6.23M +104,952 +10%
Macquarie Group
14
Macquarie Group
Australia
$54.4M +$5.9M +99,374 +9%
TCM
15
TimesSquare Capital Management
New York
$49.1M -$855K -14,398 -1%
Loomis, Sayles & Company
16
Loomis, Sayles & Company
Massachusetts
$42.8M +$2.23M +37,506 +4%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$38.1M +$1.76M +29,689 +4%
CS
18
Candriam SCA
Luxembourg
$35.1M
Northern Trust
19
Northern Trust
Illinois
$34.6M -$2.87M -48,389 -6%
BAMCO Inc
20
BAMCO Inc
New York
$33.6M -$11.4M -191,413 -21%
Goldman Sachs
21
Goldman Sachs
New York
$24.3M -$11.4M -192,787 -27%
SAM
22
Sectoral Asset Management
Quebec, Canada
$23.9M -$5.88M -99,050 -16%
PAMU
23
Pictet Asset Management (UK)
United Kingdom
$23.4M +$5.73M +96,418 +24%
Charles Schwab
24
Charles Schwab
California
$22.4M +$1.3M +21,964 +5%
SI
25
Sofinnova Investments
California
$22.1M +$8.93M +150,362 +48%

PTCT Hedge Fund Activity: Q1 2021 in Review

207 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2021, worth a combined $3.52B — down 21% from $4.46B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of PTCT and 28 opened new positions — a net loss of 4 holders — while 82 trimmed existing stakes and 75 added.

The largest buyer was RTW Investments, adding an estimated $63.7M. The largest seller was Point72 Asset Management, cutting an estimated $52.5M.

  • 207 institutional investors held PTC Therapeutics (PTCT) as of Q1 2021, down from 214 in Q4 2020.
  • Funds reported $3.52B of PTC Therapeutics stock for Q1 2021, down 21% quarter-over-quarter.
  • 28 funds opened new PTC Therapeutics positions in Q1 2021 and 32 closed out, a net change of -4 holders.
  • The largest PTC Therapeutics buyer in Q1 2021 was RTW Investments, an estimated $63.7M added.
  • The largest PTC Therapeutics seller in Q1 2021 was Point72 Asset Management, an estimated $52.5M sold.

Based on aggregated 13F filings for Q1 2021.